Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MOR106 single ascending doses, intravenous, MOR106 single ascending doses
MOR106 · 1 trial · 2 indications
To evaluate the safety and tolerability of single ascending doses of MOR106 intravenously given to healthy male subjects and of multiple ascending doses of MOR106 given intravenously to subjects with atopic dermatitis, compared to placebo
To evaluate the safety and tolerability of single ascending doses of MOR106 intravenously given to healthy male subjects and of multiple ascending doses of MOR106 given intravenously to subjects with atopic dermatitis, compared to placebo
To evaluate the safety and tolerability of single ascending doses of MOR106 intravenously given to healthy male subjects and of multiple ascending doses of MOR106 given intravenously to subjects with atopic dermatitis, compared to placebo
To evaluate the safety and tolerability of single ascending doses of MOR106 intravenously given to healthy male subjects and of multiple ascending doses of MOR106 given intravenously to subjects with atopic dermatitis, compared to placebo
To evaluate the safety and tolerability of single ascending doses of MOR106 intravenously given to healthy male subjects and of multiple ascending doses of MOR106 given intravenously to subjects with atopic dermatitis, compared to placebo
To evaluate the safety and tolerability of single ascending doses of MOR106 intravenously given to healthy male subjects and of multiple ascending doses of MOR106 given intravenously to subjects with atopic dermatitis, compared to placebo
| Arm | Type | Description |
|---|---|---|
| MOR106 | EXPERIMENTAL | Single intravenous administration of MOR106 |
| Placebo | PLACEBO_COMPARATOR | Single intravenous administration of Placebo |
| MOR106 MAD | EXPERIMENTAL | Multiple intravenous administration of MOR106 |
| Placebo MAD | PLACEBO_COMPARATOR | Multiple intravenous adminstration of Placebo |
| Name | Type | Description |
|---|---|---|
| MOR106 single ascending doses, intravenous | DRUG | - |
| Placebo single ascending doses, intravenous | DRUG | - |
| MOR106 multiple ascending doses, intravenous | DRUG | - |
| Placebo multiple intravenous administrations | DRUG | - |
Inclusion Criteria: \- Able and willing to give voluntary written informed consent Single ascending dose (SAD) * Negative urine drug screen * Male between 18-50 years of age * A body mass index (BMI) between 18-30 kg/m², inclusive. * Judged to be in good health Multiple ascending dose (MAD) * M...